Alcon and RxSight, Inc. announced a nonexclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). Under the collaboration, the companies will be innovating on their respective platforms—RxSight's postoperative light-adjustable technology and Alcon's PCIOL optical designs—and combining them to create a codeveloped technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL, both companies said in a press release. 

As part of the agreement, RxSight will receive a $60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Under the agreement, Alcon will lead global commercialization, while RxSight will be responsible for development and manufacturing and receive royalties on net sales, the companies stated in the press release. OM